Back to companies

WuXi Biologics Cayman Inc: Overview

WuXi Biologics Cayman Inc (Wuxi Biologics) provides solutions to discover, develop and manufacture biologics. The company offers protein generation, assay development, antibody generation, screening, characterization and optimization, regulatory affairs and testing services. It utilizes WuXiBody bispecific antibody platform to discover antibodies; CRISPR gene editing technology for improving cell growth and productivity; and microbial expression and fermentation platform to manufacture new proteins and plasmids. Wuxi Biologics also provide cell culture development and manufacturing, scale-out manufacturing and other services through its platform technology. The company operates production plants in China, Singapore, Ireland and the US. Wuxi Bio is headquartered in Wuxi, Jiangsu, China.

Headquarters China

Address No. 108, Meiliang Road, Mashan, Wuxi, Jiangsu


No of Employees 10,593

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange 2269 (HKG)

Revenue (2021) $1.6B 83.3% (2021 vs 2020)

EPS XXX

Net Income (2021) XXX 100.6% (2021 vs 2020)

Market Cap* $27.1B

Net Profit Margin (2021) XXX 9.4% (2021 vs 2020)

   

* As of and is in US$

Access premium data and analytics for WuXi Biologics Cayman Inc

20+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for WuXi Biologics Cayman Inc’s relevant decision makers and contact details.

18+

Pipeline Drugs

Identify which of WuXi Biologics Cayman Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

4

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

3

Clinical Trials

Determine WuXi Biologics Cayman Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

30+

Install Base

Install Base provides a holistic and a granular view of the IT product/service deployments from leading vendors. Explore IT infrastructure categories, solution and product/service areas deployed by a prospect.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on WuXi Biologics Cayman Inc’s likely spend across technology areas enabling you to understand the digital strategy.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products Services Brands
Technology Platform: Protein Generation WuXiBody
WuXiBody Bispecific Antibody Platform Assay Development WuXiDAR4
CHO K1 Cell Line Development Platform Antibody Generation, Screening, Characterization and Optimization
XXX XXX
XXX XXX
XXX XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 Corporate Changes/Expansions In November, the company launched its Integrated Biologics CRDMO Center in Fengxian, Shanghai.
2022 Corporate Awards In November, the company received the 2022 “Prime Employers for Women” silver award.
2022 Corporate Changes/Expansions In October, the company launched its drug substance GMP manufacturing facility, MFG8 in Shijiazhuang, Hebei Province, China.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters WuXi Biologics Cayman Inc CanSino Biologics Inc Innovent Biologics Inc Hainan Haiyao Co Ltd Eden Biologics Inc
Headquarters China China China China Taiwan
City Wuxi Tianjin Suzhou Haikou Zhubei
State/Province Jiangsu Tianjin Jiangsu Hainan Taipei
No. of Employees 10,593 2,191 5,538 2,589 -
Entity Type Public Public Public Public Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Ge Li, Ph.D. Chairman Executive Board 2014 54
Zhisheng Chen, Ph.D. Chief Executive Officer; Director Executive Board 2016 48
Weichang Zhou, Ph.D. Chief Technology Officer; Director; Executive Vice President Executive Board 2016 57
Ming Tu Executive Vice President; Chief Financial Officer Senior Management 2021 -
Christine Lu Wong Chief Financial Officer Senior Management 2016 52
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company Analytics

Contact the team or request a demo to find out how our data can drive your business forward

Why are you leaving?